| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ANP32B; PAL31; PHAPI2; PHAPI2a; Ssp29;;ANP32B |
| WB Predicted band size | 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human ANP32B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于PHAPI2/APRIL抗体的**示例参考文献**(注：以下内容为虚构，仅作格式参考)：
---
1. **文献名称**: *"Development and Validation of a Novel Anti-PHAPI2 Antibody for Apoptosis Studies"*
**作者**: Smith J, et al.
**摘要**: 研究团队开发了一种高特异性抗PHAPI2单克隆抗体，验证了其在免疫印迹和免疫荧光中的应用，并证实PHAPI2通过调节线粒体途径增强化疗诱导的肿瘤细胞凋亡。
2. **文献名称**: *"APRIL Neutralizing Antibody Attenuates Autoimmune Pathogenesis in Lupus Models"*
**作者**: Chen L, et al.
**摘要**: 报道了一种中和性抗APRIL抗体，可阻断APRIL与BCMA/TACI受体的结合，显著降低系统性红斑狼疮模型小鼠的自身抗体水平，缓解肾损伤。
3. **文献名称**: *"PHAPI2 Interaction with Histone Deacetylases: Insights from Antibody-Based Proteomic Analysis"*
**作者**: Kim S, et al.
**摘要**: 利用抗PHAPI2抗体进行免疫共沉淀和质谱分析，发现PHAPI2与HDAC复合物相互作用，可能参与表观遗传调控和癌症耐药性机制。
4. **文献名称**: *"Targeting APRIL in Multiple Myeloma: Preclinical Efficacy of a Humanized Antibody"*
**作者**: Rossi M, et al.
**摘要**: 人源化抗APRIL抗体在多发性骨髓瘤异种移植模型中显示出显著疗效，通过抑制肿瘤微环境中APRIL介导的生存信号通路抑制肿瘤生长。
---
**提示**：实际文献需通过PubMed、Google Scholar等平台检索关键词(如"PHAPI2 antibody"或"APRIL neutralizing antibody")。若需真实文献，请提供更具体的研究方向。
PHAPI2 (also known as APRIL, Acidic Phosphoprotein 32 Family Member B) is a member of the PHAP (Proliferation-associated protein) family, which plays roles in transcriptional regulation, apoptosis, and immune response modulation. It shares structural homology with other PHAP proteins, particularly PHAPI/APRIL-1. but exhibits distinct functional properties. PHAPI2/APRIL is implicated in regulating TNF-related apoptosis-inducing ligand (TRAIL)-mediated cell death, acting as a modulator of caspase activation and mitochondrial apoptosis pathways. Its expression is associated with tumor progression, immune evasion, and chemoresistance in cancers, making it a potential biomarker or therapeutic target.
Antibodies targeting PHAPI2/APRIL are essential tools for studying its expression, localization, and interactions in cellular models and clinical samples. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to investigate PHAPI2’s role in cancer biology, immune regulation, and apoptotic signaling. Commercial antibodies are typically validated for specificity against recombinant or endogenous PHAPI2. with applications in both basic research and translational studies. Recent studies highlight its involvement in exosome-mediated communication and metastasis, driving demand for reliable detection reagents. However, users must verify cross-reactivity with other PHAP family members to ensure experimental accuracy.
×
